| Project/Area Number |
18K19741
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 59:Sports sciences, physical education, health sciences, and related fields
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-06-29 – 2023-03-31
|
| Project Status |
Completed (Fiscal Year 2022)
|
| Budget Amount *help |
¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2019: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | Ⅰ型アレルギー / 腸上皮細胞 / ガレクチン９ / フコイダン / コンブ / アレルギー / 抗アレルギー / 海藻類 / TLR9 / 共培養 / アレルギー抑制 / Toll-like receptor 9 / 陰イオン交換クロマトグラフィー / イムノグロブリンE / 肥満細胞 / レクチン / 自然免疫 |
|---|
| Outline of Final Research Achievements |
To clarify the mechanism of Galectin 9 (Gal9) production by fucoidan administration, a culture system consisting of HT-29/RBL-2H3 cells was first constructed. It was demonstrated that the amount of Gal9 secreted to the basolateral side was increased with dose-dependent manner, and the amount of Gal9 secreted and Gal9 mRNA expression increased over time depending on the amount of fucoidan added. Furthermore, degranulation of RBL-2H3 cells was also suppressed. Next, to clarify the involvement of TLR9 as the fucoidan receptor, we evaluated its effect on Gal9 release using a TLR9 knockdown strain of HT-29 cells transfected with a TLR9 siRNA sequence. As a result, a decrease in the amount of Gal9 secreted to the basolateral side was observed upon TLR9 knockdown. In conclusion, we demonstrated that oral fucoidan suppresses type I allergy by producing Gal9 in the blood via TLR9 receptors expressed on intestinal epithelial cells.
|
| Academic Significance and Societal Importance of the Research Achievements |
フコイダン経口摂取により、TLR9を介してIgE高親和性のガレクチン9が血中に分泌されるので、例えば既に花粉症などのアレルギー疾患を罹患した後でもその発症を抑制できることを示唆しており、これまでの抗アレルギー抑制機構とは全く異なった新規抑制機構を提唱できる。すなわち、これまでアレルギーを抑制する目的で着目されて来たTh1/Th2バランスの崩れを改善することを目的としていないため、細胞性あるいは体液性免疫への影響することなくアレルギーを改善できる可能性がある。
|
